Skip to main content

Ph 2a multicenter, randomized, open label, two part adaptive design study to evaluate the antiviral effect safety and tolerability of GSK 3810109A, an HIV-1 specific broadly neutralizing human monoclonal antibody in antiretroviral naive HIV-1 adults

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Infectious Diseases

Awarded By

ViiV Healthcare

Start Date

June 25, 2021

End Date

October 24, 2023
 

Administered By

Medicine, Infectious Diseases

Awarded By

ViiV Healthcare

Start Date

June 25, 2021

End Date

October 24, 2023